Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hologic ( (HOLX) ) has provided an announcement.
On October 21, 2025, Hologic, Inc. announced its entry into a definitive agreement to be acquired by Blackstone and TPG for up to $79 per share, valuing the company at approximately $18.3 billion. This acquisition, which includes a 46% premium on Hologic’s stock price prior to media reports, aims to strengthen Hologic’s leadership in women’s health and accelerate its growth. The transaction is expected to close in the first half of 2026, pending shareholder and regulatory approvals, and will result in Hologic’s delisting from Nasdaq. The deal includes significant minority investments from ADIA and GIC, and Hologic’s stockholders will receive $76 per share in cash plus a contingent value right of up to $3 per share based on future revenue milestones.
The most recent analyst rating on (HOLX) stock is a Hold with a $73.00 price target. To see the full list of analyst forecasts on Hologic stock, see the HOLX Stock Forecast page.
Spark’s Take on HOLX Stock
According to Spark, TipRanks’ AI Analyst, HOLX is a Neutral.
Hologic’s overall stock score is driven by a positive earnings call that highlighted strong financial performance and strategic growth initiatives. However, declining profitability margins and a high P/E ratio weigh on the score. Technical indicators suggest a neutral market sentiment.
To see Spark’s full report on HOLX stock, click here.
More about Hologic
Hologic, Inc. is a global leader in women’s health, focusing on developing innovative medical technologies for detection, diagnosis, and treatment of health conditions, aiming to raise the standard of care worldwide.
Average Trading Volume: 1,913,942
Technical Sentiment Signal: Strong Buy
Current Market Cap: $15.99B
For a thorough assessment of HOLX stock, go to TipRanks’ Stock Analysis page.